XML 45 R37.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Summary of Disaggregated Amounts that Comprise Research and Development and General and Administrative Expenses

In addition to the significant expense categories included within consolidated net income (loss) presented on the Company's condensed consolidated statements of operations and comprehensive income (loss), see below for disaggregated amounts that comprise research and development and general and administrative expenses:

 

THREE MONTHS ENDED
MARCH 31,

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

Research and development:

 

 

 

 

 

 

Clinical development

 

$

4,834

 

 

$

1,245

 

Employee-related

 

 

4,118

 

 

 

2,152

 

Facility and equipment costs

 

 

347

 

 

 

378

 

Pre-clinical research

 

 

26

 

 

 

117

 

Other research and development segment expenses

 

 

515

 

 

 

124

 

Total research and development

 

 

9,840

 

 

 

4,016

 

General and administrative:

 

 

 

 

 

 

Employee-related

 

 

2,366

 

 

 

1,716

 

Professional and consulting fees

 

 

2,049

 

 

 

1,803

 

Commercial readiness

 

 

1,338

 

 

 

131

 

Other general and administrative segment expenses (1)

 

 

691

 

 

 

464

 

Total general and administrative

 

 

6,444

 

 

 

4,114

 

Total operating expenses

 

 

16,284

 

 

 

8,130

 

Loss from operations

 

 

(16,284

)

 

 

(8,130

)

Grant income

 

 

22

 

 

 

 

Interest income

 

 

1,322

 

 

 

934

 

Interest expense

 

 

(1,564

)

 

 

(306

)

Change in fair value of warrant liabilities

 

 

7,643

 

 

 

14,881

 

Net income (loss)

 

$

(8,861

)

 

$

7,379

 

(1) Other general and administrative segment expenses primarily consist of insurance, recruiting, occupancy, and information technology costs.